SC
DNTH icon

Steven Cohen’s Dianthus Therapeutics DNTH Stock Holding History

Steven Cohen’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-643,599
Closed -$54M – 4141
2026
Q1 		$54M Sell
643,599
-522,489
-45% -$30.3M 0.07% 338
2025
Q4 		$48.1M Sell
1,166,088
-875,872
-43% -$34M 0.05% 422
2025
Q3 		$80.4M Buy
2,041,960
+649,443
+47% +$16.6M 0.13% 167
2025
Q2 		$25.9M Sell
1,392,517
-94,427
-6% -$1.77M 0.05% 416
2025
Q1 		$27M Buy
1,486,944
+1,293,344
+668% +$28.5M 0.06% 363
2024
Q4 		$4.22M Sell
193,600
-244,100
-56% -$6.28M 0.01% 1008
2024
Q3 		$12M Buy
437,700
+263,500
+151% +$7.34M 0.03% 584
2024
Q2 		$4.51M Sell
174,200
-177,900
-51% -$4.28M 0.01% 861
2024
Q1 		$10.6M Buy
+352,100
New +$7.65M 0.03% 696
2018
Q3 		– Sell
-506
Closed -$109K – 1052
2018
Q2 		$109K Buy
+506
New +$114K ﹤0.01% 931

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Steven Cohen's DNTH Position: Q2 2026 in Review

Steven Cohen sold out of Dianthus Therapeutics (DNTH) in Q2 2026, closing a stake of 643,599 shares — an estimated $54M sold.

Steven Cohen first reported a position in DNTH in Q2 2018 and held it in 10 quarters. The position peaked at $80.4M in Q3 2025. 267 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Steven Cohen reported no remaining Dianthus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Steven Cohen sold 643,599 Dianthus Therapeutics shares in Q2 2026, an estimated $54M.
  • Steven Cohen first reported a position in Dianthus Therapeutics in Q2 2018 and held it in 10 quarters.
  • Steven Cohen's Dianthus Therapeutics position peaked at $80.4M in Q3 2025.
  • 267 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.